Viewing Study NCT01458392

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 3:23 PM

Ignite Modification Date: 2026-01-02 @ 3:31 AM

Study NCT ID: NCT01458392

Status: COMPLETED

Last Update Posted: 2022-10-05

First Post: 2011-10-20

Is NOT Gene Therapy: True

Has Adverse Events: True

Brief Title: Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck

Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module Adverse Events Module Baseline Characteristics Module Participant Flow Module